PORTFOLIO NEWS Carmot Therapeutics Expands Leadership Team and Closes $47M Series C Financing to Advance Novel Incretin Receptor Modulators Through Phase 2 Studies September 30, 2020 Read More » Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases September 17, 2020 Read More » Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors September 16, 2020 Read More » Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies September 15, 2020 Read More » Hexagon Bio: This Biotech Startup Just Raised $47 Million To Make Drugs From Fungi September 15, 2020 Read More » Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies September 15, 2020 Read More » Escient Pharmaceuticals Raises $77.5 Million Series B Round And Initiates A Phase 1/1b Clinical Trial Of EP547, A MRGPR-Targeted Therapy To Treat Cholestatic And Uremic Pruritus September 14, 2020 Read More » Casma Therapeutics Announces $50 Million Series B Financing September 10, 2020 Read More » NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study August 29, 2020 Read More » RAPT Therapeutics Reports Second Quarter 2020 Financial Results August 13, 2020 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Carmot Therapeutics Expands Leadership Team and Closes $47M Series C Financing to Advance Novel Incretin Receptor Modulators Through Phase 2 Studies September 30, 2020 Read More »
Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases September 17, 2020 Read More »
Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors September 16, 2020 Read More »
Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies September 15, 2020 Read More »
Hexagon Bio: This Biotech Startup Just Raised $47 Million To Make Drugs From Fungi September 15, 2020 Read More »
Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies September 15, 2020 Read More »
Escient Pharmaceuticals Raises $77.5 Million Series B Round And Initiates A Phase 1/1b Clinical Trial Of EP547, A MRGPR-Targeted Therapy To Treat Cholestatic And Uremic Pruritus September 14, 2020 Read More »
NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study August 29, 2020 Read More »
